Vanguard Group Inc. Increases Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Vanguard Group Inc. lifted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,615,223 shares of the medical technology company's stock after acquiring an additional 80,101 shares during the quarter. Vanguard Group Inc. owned approximately 3.39% of Alphatec worth $59,859,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. increased its holdings in Alphatec by 24.5% in the third quarter. American Century Companies Inc. now owns 2,655,328 shares of the medical technology company's stock worth $34,440,000 after purchasing an additional 523,323 shares in the last quarter. Walleye Trading LLC increased its holdings in Alphatec by 5.0% in the third quarter. Walleye Trading LLC now owns 50,353 shares of the medical technology company's stock worth $653,000 after purchasing an additional 2,375 shares in the last quarter. Walleye Capital LLC increased its holdings in Alphatec by 13.1% in the third quarter. Walleye Capital LLC now owns 795,525 shares of the medical technology company's stock worth $10,318,000 after purchasing an additional 92,174 shares in the last quarter. Invst LLC increased its holdings in Alphatec by 15.0% in the third quarter. Invst LLC now owns 152,919 shares of the medical technology company's stock worth $1,983,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Comerica Bank bought a new stake in Alphatec in the third quarter worth approximately $36,000. 66.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ATEC shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Monday, March 4th. Wells Fargo & Company assumed coverage on Alphatec in a report on Friday, February 9th. They set an "overweight" rating and a $26.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and set a $25.00 price objective on shares of Alphatec in a report on Wednesday, March 20th. Finally, Needham & Company LLC boosted their price objective on Alphatec from $22.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, March 28th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat, Alphatec presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.63.

Alphatec Stock Up 1.4 %

Shares of NASDAQ:ATEC traded up $0.20 during mid-day trading on Monday, hitting $14.00. 1,072,387 shares of the company traded hands, compared to its average volume of 1,675,625. The stock has a market cap of $1.93 billion, a P/E ratio of -9.03 and a beta of 1.55. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54. Alphatec Holdings, Inc. has a 12-month low of $8.66 and a 12-month high of $19.14. The stock has a 50-day moving average price of $14.54 and a two-hundred day moving average price of $13.40.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The company had revenue of $138.00 million during the quarter, compared to the consensus estimate of $131.90 million. The firm's revenue was up 30.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.33) earnings per share. On average, equities research analysts forecast that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current year.

Insiders Place Their Bets

In other Alphatec news, General Counsel Tyson Eliot Marshall sold 11,825 shares of the business's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $13.30, for a total value of $157,272.50. Following the transaction, the general counsel now owns 305,095 shares of the company's stock, valued at $4,057,763.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Alphatec news, CFO John Todd Koning sold 121,601 shares of the business's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $13.30, for a total value of $1,617,293.30. Following the transaction, the chief financial officer now owns 430,856 shares of the company's stock, valued at $5,730,384.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Tyson Eliot Marshall sold 11,825 shares of the business's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $13.30, for a total value of $157,272.50. Following the completion of the transaction, the general counsel now directly owns 305,095 shares in the company, valued at approximately $4,057,763.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 250,069 shares of company stock valued at $3,528,245. Insiders own 29.12% of the company's stock.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.